Stock listing

HTD Stock Price, News, Filings & Events — Corcept Therapeutics Incorporated

Selected listing: HTD · DUS · EUR · DE

This page tracks Corcept Therapeutics Incorporated's HTD:DUS listing on DUS in EUR for DE, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following HTD:DUS. HTD:DUS is the stock-level entry point for investors researching Corcept Therapeutics Incorporated, while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary. Corcept Therapeutics Incorporated (CORT) is a publicly traded company based in the United States, with a market capitalization of approximately $10.24 billion. The company focuses on developing and commercializing innovative therapies for the treatment of various medical conditions. Corcept is committed to advancing its research and providing effective solutions for patients.

HTD:DUSEURDEUpdated August 28, 2026

Ticker: HTD:DUS
Asset type: Stock
Market cap: $12.31B
Sector: Health Technology
Industry: Pharmaceuticals: Major
Exchange: DUS
Currency: EUR

Corcept Therapeutics Incorporated HTD:DUS stock context

Latest news from Corcept Therapeutics Incorporated

CORRECTION FROM SOURCE: Corton Capital Inc. Announces August 2026 Distributions for the Exchange Traded Fund

August 25, 2026

Corcept Resubmits New Drug Application for Relacorilant as a Treatment for Patients with Cushing’s Syndrome

June 17, 2026

Corcept Presents New Data at ADA: Improved Outcomes in Patients Receiving a GLP-1 with Difficult-to-Control Type 2 Diabetes and Hypercort...

June 6, 2026

Corcept Presents New Data at ASCO 2026: Lifyorli™ Overall Survival Across All Subgroups of Patients with Platinum-Resistant Ovarian Cance...

May 29, 2026

Corcept to Resubmit its New Drug Application for Relacorilant as a Treatment for Patients with Cushing’s Syndrome

May 27, 2026

All Corcept Therapeutics Incorporated news →

Corcept Therapeutics Incorporated earnings calls

Corcept Therapeutics Incorporated (CORT) Q2 2026 Earnings Call

July 29, 2026 · Replay with transcript and chapters

Corcept Therapeutics Incorporated (CORT) Q1 2026 Earnings Call

April 30, 2026 · Replay with transcript and chapters

Corcept Therapeutics Incorporated (CORT) Q4 2025 Earnings Call

February 24, 2026 · Replay with transcript and chapters

Corcept Therapeutics Incorporated (CORT) Q3 2025 Earnings Call

November 4, 2025 · Replay with transcript and chapters

Corcept Therapeutics Incorporated (CORT) Q2 2025 Earnings Call

July 31, 2025 · Replay with transcript and chapters

Corcept Therapeutics Incorporated (CORT) Q1 2025 Earnings Call

May 5, 2025 · Replay with transcript and chapters

Research Corcept Therapeutics Incorporated

Corcept Therapeutics Incorporated investor report

Review AI stock analysis and investor report context for HTD:DUS.

Corcept Therapeutics Incorporated company profile

View the public company page for Corcept Therapeutics Incorporated on 6ix.

Corcept Therapeutics Incorporated news

Read company news and market updates connected to Corcept Therapeutics Incorporated.

Corcept Therapeutics Incorporated investor events

Find investor webinars, events, and replay context for Corcept Therapeutics Incorporated.